COMMUNIQUÉS West-GlobeNewswire

-
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
01/05/2024 -
Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow
01/05/2024 -
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
01/05/2024 -
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
01/05/2024 -
WAKE RADIOLOGY TEAM RALLIES TO SUPPORT TRIANGLE RACE FOR THE CURE
01/05/2024 -
Seasoned Physician Executive Joins Nymbl Science
01/05/2024 -
Simms/Mann Family Foundation Recognizes Extraordinary Nurses in Second Year of “Off the Chart: Rewarding Nursing Greatness” Campaign
01/05/2024 -
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
01/05/2024 -
H1 Appoints Seasoned Marketing & Technology Executive Karen Walker to Its Board of Directors
01/05/2024 -
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01/05/2024 -
Aeroflow Health Announces Expanded Access to Lactation Consultants, Supporting New Mothers Across all 50 States
01/05/2024 -
The Pediatric Brain Tumor Foundation Welcomes Dr. Sanjay Gupta to its Board of Directors
01/05/2024 -
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
01/05/2024 -
WeightWatchers for Business and Personify Health Partner to Help Employers Address Weight Health Care
01/05/2024 -
SFWJ/MedCana Reacts to US DEA's Rescheduling of Marijuana
01/05/2024 -
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
01/05/2024 -
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
01/05/2024 -
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
01/05/2024 -
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
01/05/2024
Pages